DelveInsight Business Research LLP

DelveInsight’s “Rhinitis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Rhinitis pipeline landscapes. 

The report comprises Rhinitis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Rhinitis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Rhinitis pipeline products.  

Rhinitis Overview

Rhinitis is also known as coryza, is irritation and inflammation of the mucous membrane inside the nose. Common symptoms are a stuffy nose, runny nose, sneezing, and post-nasal drip. The inflammation is caused by viruses, bacteria, irritants or allergens.

Rhinitis is classified as allergic or nonallergic. The cause of nonallergic rhinitis is usually a viral infection, although irritants can cause it. The nose is the most commonly infected part of the upper airways.

Rhinitis may be acute (short-lived) or chronic (long-standing). Acute rhinitis commonly results from viral infections but may also be a result of allergies, bacteria, or other causes. Chronic rhinitis usually occurs with chronic sinusitis (chronic rhinosinusitis).

Some of the key takeaways from the Rhinitis Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as EMS, Regeneron Pharmaceuticals, ALK-Abelló A/S, Bayer, Inmunotek S.L, Allergy Therapeutics, etc., are developing therapies for the treatment of Rhinitis.

• Emerging therapies such as Magnólia Nasal Gel, Anti-Bet v 1, HDM SLIT-tablet , Azelastine hydrochloride (BAYR9258), MM09-SIT-023 , PQ Grass 27600 SU, are expected to have a significant impact on the  Rhinitis market in the coming years.

Get an overview of pipeline landscape @ Rhinitis Clinical Trials Analysis 

Rhinitis Pipeline Therapies along with Key Players:

• Magnólia Nasal Gel: EMS

• Anti-Bet v 1: Regeneron Pharmaceuticals

• HDM SLIT-tablet: ALK-Abelló A/S

• Azelastine hydrochloride (BAYR9258): Bayer

•  MM09-SIT-023: Inmunotek S.L

• PQ Grass 27600 SU: Allergy Therapeutics

Scope of Rhinitis Pipeline Drug Insight    

• Coverage: Global 

• Major Players: EMS, Regeneron Pharmaceuticals, ALK-Abelló A/S, Bayer, Inmunotek S.L, Allergy Therapeutics, and others.

• Pipeline Therapies: Magnólia Nasal Gel, Anti-Bet v 1, HDM SLIT-tablet , Azelastine hydrochloride (BAYR9258), MM09-SIT-023 , PQ Grass 27600 SU, and others.

Table of Contents

Get a customized pipeline report @ Rhinitis Drugs Pipeline Report.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/